BEIJING, China--(BUSINESS WIRE)-- Bonovo Orthopedics, Inc., a leading provider of orthopedic products to the Chinese healthcare market, announced today that it closed a US$10 million Series C Preferred Stock financing. The financing was led by OrbiMed Asia Partners and was participated in by Legend Capital and Bonovo’s existing shareholders. The Series C round brings Bonovo’s total capital raised to US$16.5 million. Uses of the Series C funds include further expanding Bonovo’s Chinese sales platform and accelerating the Company’s robust product development programs.
Bonovo Orthopedics, Inc. manufactures and distributes orthopedic implants and other orthopedic products for the Chinese healthcare market. The Company was formed in July of 2008 through the merger of three China-based companies with over 15 years of experience in manufacturing and sales of orthopedic products. With two ISO-certified manufacturing facilities and offices located throughout China, Bonovo has quickly become a leading medical device company in the Chinese healthcare market. The Company’s vast surgeon network serves as a bridge between the “East” and the “West” for surgeon training.
Bonovo’s product line includes spinal implants, artificial joints, pain management and minimally invasive surgical solutions. The Company distributes proprietary products under such brand names as ALPS®, Great Wall® and NovoplastyTM, and serves as the exclusive China distribution partner for international orthopedic companies, such as NuVasive, Pioneer Surgical Technologies and Japan Medical Materials.
According to Peter Slate, Chief Executive Officer of Bonovo Orthopedics, “OrbiMed and Legend have brought a wealth of global resources to Bonovo. We will benefit from their deep understanding of the healthcare market and strong China experience.” Chip Bao, PhD, President of Bonovo Asia, stated that, “The Series C capital raise provides Bonovo with ‘scale-up’ capital to continue our growth in China and throughout Asia.”
“Bonovo has built a powerful platform to introduce advanced orthopedic technology and products to the rapidly growing Chinese market,” Dr. Jonathan Wang, Senior Managing Director of OrbiMed Asia, said. “Leveraging OrbiMed’s global network and resources, we will do our best to help Bonovo enhance this platform.” Bonovo’s Series C financing was the latest among the over 10 Asia-related investments OrbiMed had made over the past 12 months. Dr. Wang has joined Bonovo’s Board of Directors.
About Bonovo
Bonovo is a leading provider of orthopedic products to the Chinese healthcare market. Bonovo distributes its own products and serves as a distribution partner for other leading international companies. The Bonovo team is committed to driving new standards of orthopedic care throughout China by bringing the best products to market – Products that combine strong market demand with great social benefit. For more information on Bonovo and its products visit www.bonovo-ortho.com.
About OrbiMed
OrbiMed is the world’s largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed has invested in over 110 private companies across a wide range of therapeutic categories and stages of development. In 2008, OrbiMed created the first Pan-Asia healthcare and life sciences-dedicated venture capital fund. They have offices in New York, Shanghai, Mumbai, Tel Aviv and San Francisco. You can obtain additional information on OrbiMed at www.orbimed.com.
About Legend Capital
Legend Capital is headquartered in Beijing, with an office in Shanghai. Managing close to US$800 million across four U.S. dollar funds and one RMB fund, Legend invests in high-growth enterprises with operations in China and foreign companies with markets in China. Legend has a team of 35 investment professionals in China. Legend focuses on venture capital and growth capital investments, and is a lead or co-lead investor of US$5-20 million in more than 100 enterprises. More information about Legend is available at www.legendcapital.com.cn.
